Source: BioPharma-Reporter

Intergalactic: Intergalactic plans to progress non-viral gene therapy program into the clinic

Intergalactic Therapeutics, a startup focused on non-viral gene therapy, reports positive preclinical results for its lead program, IG-002, addressing all forms of ABCA4-related retinopathies.

Read full article »

Intergalactic's Competitors | Intergalactic's News | Intergalactic's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

25-100

CEO

Theresa G H Heah

CEO Approval Rating

90/100

Intergalactic is a Massachusetts-based biotechnology company that reserches and develops non-viral gene therapies for the treatment of CNS and musculoskeletal disorders.